Who We Are Founded in 2017, Unit8 is a fast-growing Swiss AI and data analytics consulting and services company dedicated to solving complex problems of traditional industries like automotive, chemical, financial services, manufacturing and pharma. We work
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS‑addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON)